GLP-1 drugs reduce heart failure hospitalizations and cardiovascular death across metabolic conditions—except possibly HFrEF | Research

The takeaway

Meta-analysis of 15 trials (87,549 patients) shows GLP-1RAs reduce composite HFH/CV death in heart failure (HR 0.81), diabetes (HR 0.85), and obesity (HR 0.70), but may increase HFH in HFrEF (HR 1.17, NS) while reducing CV death (HR 0.67).

30% reduction in obesity
GLP-1 drugs reduced composite HFH/CV death by 30% in obese patients—the largest effect among all metabolic conditions studied

What the researchers found

Composite HFH/CV death: HF HR 0.81, T2DM HR 0.85, obesity HR 0.70, CKD HR 0.79 (NS). CV death reduced in HF (HR 0.88), T2DM (HR 0.85), obesity (HR 0.83). HFrEF exception: HFH HR 1.17 (NS) but CV death HR 0.67 (significant). No increased SAEs (RR 0.94).

Why it matters

This provides the most comprehensive evidence yet that GLP-1 drugs benefit the heart across multiple metabolic conditions. The HFrEF signal—possible HF hospitalization increase despite mortality benefit—is a critical nuance for clinical decision-making.

How the study worked

Meta-analysis of 15 trials (87,549 patients) from databases through November 2024. Random-effects models for HRs and RRs. Subgroup analyses by disease type and combination.

What this study cannot tell us

CKD results non-significant. HFrEF signal based on limited data. Post hoc subgroup analyses. Heterogeneity across trials in patient populations and GLP-1 agents. Meta-analysis cannot determine mechanisms.

How to read the evidence

Large meta-analysis of 15 RCTs (87,549 patients). High-quality evidence synthesis with important subgroup findings.

When this study was published

Published in 2025; databases through November 2024.

The bigger picture

This meta-analysis helps resolve questions about which patients benefit most from GLP-1 drugs for cardiovascular protection. The consistent benefits across conditions support broad use, while the HFrEF caution highlights the need for dedicated trials in this specific population.

Questions still open

Why might GLP-1 drugs increase HFH in HFrEF despite reducing CV death?
Should GLP-1 drugs be avoided in HFrEF until dedicated trials are completed?
Do the benefits differ between specific GLP-1 agonists?

Common questions

Do GLP-1 drugs help with heart failure?

Yes, in most cases. This large analysis of 87,549 patients shows GLP-1 drugs reduce heart failure hospitalizations and cardiovascular death in patients with diabetes, obesity, and heart failure with preserved function. However, in patients with weakened heart pumping (HFrEF), there may be a slight increase in hospitalizations despite reduced death risk.

Are GLP-1 drugs safe for the heart?

Overall, very safe. No increase in serious adverse events was found. The drugs reduced cardiovascular death across all metabolic conditions studied. The only caution is for patients with severely weakened hearts (HFrEF), where more research is needed.

Read the original research

Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity.

European journal of heart failure, 27(12), 2844-2854

View on PubMed ↗Publisher’s paper ↗

Citation

Siddiqi, Tariq Jamal; Khan, Muhammad Shahzeb; Waqas, Saad Ahmed; Van Spall, Harriette G C; Shapiro, Michael D; Fonarow, Gregg C; Januzzi, James L; Afzal, Aasim M; Pandey, Ambarish; Butler, Javed; Greene, Stephen J. (2025). Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity.. European journal of heart failure, 27(12), 2844-2854. https://doi.org/10.1002/ejhf.70048